Rupee Closes 41 Paise Lower Against Dollar Ahead Of RBI Policy
The rupee closed weaker against the US dollar on Tuesday, extending its losses from the previous session. Investors are expected to remain cautious ahead of the Reserve Bank of India's policy decision and they will continue to assess the impact of US tariffs.
The domestic currency weakened 41 paise to close at 86.25 per dollar after opening at 85.88. It had settled at 85.84 on Monday. During the session, the rupee briefly crossed the 86 mark to touch an intraday low of 86.08. Brent crude was up 0.05% at $64.24 per barrel, while the spot dollar index rose 0.08% to 103.3430.
The sharp moves seen earlier in global markets eased slightly on Tuesday, with investors in Asia turning to bargain-hunting while awaiting clarity on US President Donald Trump's tariff plans. Markets are watching for how Washington and its trading partners respond to the latest round of tariff escalation.

Traders will also shift focus to the RBI Monetary Policy Committee meeting on Wednesday. Governor Sanjay Malhotra's statement and press conference will be closely watched for any cues on how the central bank views the impact of Trump's 26% tariff on Indian exports. Most economists surveyed by Bloomberg expect a 25-basis point rate cut to 6%, while some anticipate a deeper cut or a change in policy stance to ‘accommodative'.
Meanwhile, in a report released Tuesday, Crisil Ratings warned that sharp rupee volatility could dent earnings of several sectors by up to 250 basis points in the next financial year. The most vulnerable include complex fertilisers, airlines, oil and gas, capital goods, pharmaceuticals, and renewable energy—sectors with high imported input costs and unhedged foreign debt exposure.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.